Preclinical data from tumors with high EGFR expression, such as head and neck squamous cell carcinoma (HNSCC) and colorectal carcinoma, further support the potential application of the EGFR/CD3 bispecific antibody in cSCC. Here, EGFR is linked to skin squamous cell carcinoma.